文献速递肾移植

免疫调节纳米颗粒靶向炎症单核细胞预防急性肾同种异体移植排斥

Targeting inflammatory monocytes by immune-modifying nanoparticles prevents acute kidney allograft rejection.
PubMed 文献 · Kidney Int · 2022-07-16

该研究在小鼠肾移植模型中,将带负电荷、直径500纳米的聚苯乙烯免疫调节纳米颗粒(IMPs)输注给同种异体移植小鼠,发现其通过结合炎症单核细胞并诱导其凋亡,显著减轻急性排斥反应、改善肾功能,但未能预防慢性排斥。

要点

  • IMPs输注组同种异体移植小鼠生存优于对照组,急性排斥反应显著减轻
  • IMPs减少移植肾中炎症细胞浸润、细胞因子和细胞毒分子表达及血清供体特异性IgG2c抗体滴度
  • IMPs未能保护同种异体移植小鼠免于慢性排斥反应

核心结论

  • IMPs通过抑制固有免疫和适应性同种免疫,对急性排斥反应提供显著保护作用。
  • 结合既往在肾缺血再灌注损伤中的保护作用,IMPs被认为是肾移植中潜在的诱导治疗药物。

研究设计与样本

  • 研究为小鼠肾移植实验,从BALB/c(H2d)到C57BL/6(H2b)进行移植。
  • 实验分两组:对照组(同种异体移植组,allo)和输注IMPs的同种异体移植组。
  • 两组分别观察14天(急性排斥)或100天(慢性排斥)。

主要发现

  • 与同种异体移植组相比,输注IMPs的同种异体移植组小鼠在14天时生存更优、急性排斥反应明显减轻、肾功能更好、肾小管炎更少、移植肾中炎症细胞密度及细胞因子和细胞毒分子表达降低、血清供体特异性IgG2c抗体滴度更低。
  • 与同种异体移植组相比,输注IMPs的同种异体移植组小鼠肾脏中Ly6Chi单核细胞、CD11b+细胞和NKT+细胞减少。
  • IMPs主要结合血流中的CD11b+细胞以及脾脏中的CD11b+细胞和CD11c-B220+边缘区B细胞。
  • 在脾脏中,IMPs主要位于红髓,与MARCO及cleaved caspase-3表达共定位。
  • 在100天时,输注IMPs的同种异体移植组小鼠巨噬细胞M1反应降低,但未免受慢性排斥反应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inflammatory monocytes are a major component of the cellular infiltrate in acutely rejecting human kidney allografts. Since immune-modifying nanoparticles (IMPs) bind to circulating inflammatory monocytes via the specific scavenger receptor MARCO, causing diversion to the spleen and subsequent apoptosis, we investigated the therapeutic potential of negatively charged, 500-nm diameter polystyrene IMPs to prevent kidney allograft rejection. Kidney transplants were performed from BALB/c (H2d) to C57BL/6 (H2b) mice in two groups: controls (allo) and allo mice infused with IMPs. Groups were studied for 14 (acute rejection) or 100 (chronic rejection) days. Allo mice receiving IMPs exhibited superior survival and markedly less acute rejection, with better kidney function, less tubulitis, and diminished inflammatory cell density, cytokine and cytotoxic molecule expression in the allograft and lower titers of donor-specific IgG2c antibody in serum at day 14, as compared to allo mice. Cells isolated from kidneys from allo mice receiving IMPs showed reduced Ly6Chi monocytes, CD11b+ cells and NKT+ cells compared to allo mice. IMPs predominantly bound CD11b+ cells in the bloodstream and CD11b+ and CD11c-B220+ marginal zone B cells in the spleen. In the spleen, IMPs were found predominantly in red pulp, colocalized with MARCO and expression of cleaved caspase-3. At day 100, allo mice receiving IMPs exhibited reduced macrophage M1 responses but were not protected from chronic rejection. IMPs afforded significant protection from acute rejection, inhibiting both innate and adaptive alloimmunity. Thus, our current experimental findings, coupled with our earlier demonstration of IMP-induced protection in kidney ischemia-reperfusion injury, identify IMPs as a potential induction agent in kidney transplantation.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Lai C, Chadban SJ, Loh YW, et al. Targeting inflammatory monocytes by immune-modifying nanoparticles prevents acute kidney allograft rejection. Kidney Int. 2022. PMID: 35850291. doi:10.1016/j.kint.2022.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。